New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 0.1 ic/ml (chicken (33%), duck (33%), goose (33%) feathers extract); allergen extracts 1 ic/ml (chicken (33%), duck (33%), goose (33%) feathers extract); allergen extracts 10 ic/ml (chicken (33%), duck (33%), goose (33%) feathers extract) - solution for injection - active: allergen extracts 0.1 ic/ml (chicken (33%), duck (33%), goose (33%) feathers extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 1 ic/ml (chicken (33%), duck (33%), goose (33%) feathers extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 10 ic/ml (chicken (33%), duck (33%), goose (33%) feathers extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 0.1 ic/ml (rumex acetosa pollen extract); allergen extracts 1 ic/ml (rumex acetosa pollen extract); allergen extracts 10 ic/ml (rumex acetosa pollen extract) - solution for injection - active: allergen extracts 0.1 ic/ml (rumex acetosa pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 1 ic/ml (rumex acetosa pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 10 ic/ml (rumex acetosa pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

United States - English - NLM (National Library of Medicine)

allermed laboratories, inc. - dermatophagoides farinae (unii: pr9u2ypf3q) (dermatophagoides farinae - unii:pr9u2ypf3q) - dermatophagoides farinae 10000 [au] in 1 ml - standardized mite extract is indicated for use in the diagnosis of patients with a history of allergy to mites or house dust and for the treatment of patients with a history of mite allergy who have established sensitivity to mites by diagnostic skin testing. the use of mite extract for the above purposes should be made only by physicians with special familiarity and knowledge of allergy as described in a standard allergy textbook 10 . injections of mite extract should not be administered in the presence of diseases characterized by a bleeding diathesis. immunotherapy should not be started in patients until a specific diagnosis of type i allergy to mite is made by a physician based on skin testing with this product. other contraindications include: extreme sensitivity to mite: determined from previous anaphylaxis following skin testing, immunotherapy, or natural exposure. autoimmune disease: individuals with autoimmune disease maybe at risk, due to the possibility of routine immunizations e

Ireland - English - HPRA (Health Products Regulatory Authority)

stallergenes - dermatophagoides pteronyssinus extract; dermatophagoides farinae extract - sublingual tablet - 100 & 300 index of reactivity - house dust mites

Ireland - English - HPRA (Health Products Regulatory Authority)

stallergenes - dermatophagoides pteronyssinus extract; dermatophagoides farinae extract - sublingual tablet - 100 index of reactivity - house dust mites

Ireland - English - HPRA (Health Products Regulatory Authority)

stallergenes - dermatophagoides pteronyssinus extract; dermatophagoides farinae extract - sublingual tablet - 300 index of reactivity - house dust mites

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - olea europaea, quantity: 10 ir/ml - injection, suspension - excipient ingredients: sodium chloride; phenol; mannitol; aluminium hydroxide hydrate; water for injections - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

United States - English - NLM (National Library of Medicine)

allergy laboratories, inc. - dermatophagoides farinae (unii: pr9u2ypf3q) (dermatophagoides farinae - unii:pr9u2ypf3q) - dermatophagoides farinae 10000 [au] in 1 ml - standardized mite extract is used for the diagnosis and treatment of allergic disease to mite. diagnosis of allergic disease to mite is made through a combined medical history sufficiently complete to identify allergic symptoms to mite and identification of mite allergy by diagnostic skin testing. hyposensitization therapy to mite is treatment for patients exhibiting allergic reactions to mite. immunotherapy is intended for patients whose symptoms cannot be satisfactorily controlled by avoidance of the offending allergen or by the use of symptomatic medications. (5) there are no known absolute contraindications to hyposensitization therapy. see precautions section for pregnancy risks. a patient should not be treated with allergens unless a history of symptoms and a positive skin test reaction have been demonstrated. allergenic extracts should only be administered to patients that show symptoms of allergy or asthma. the physician must determine if the benefits outweigh the risks in using these products for tre

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - dust allergens, quantity: 0.97 ml/ml (equivalent: dust allergens, qty 97 mg/ml); dust allergens, quantity: 0.01 ml/ml (equivalent: dust allergens, qty 1 mg/ml); feathers, quantity: 0.003 ml/ml (equivalent: feathers, qty 0.3 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - american house dust mite extract, quantity: 5 ir/ml; european house dust mite extract, quantity: 5 ir/ml - injection, suspension - excipient ingredients: sodium chloride; phenol; water for injections; aluminium hydroxide hydrate; mannitol - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.